CA2126619A1 - Sustained-release preparation of anti-endothelin substance - Google Patents

Sustained-release preparation of anti-endothelin substance

Info

Publication number
CA2126619A1
CA2126619A1 CA002126619A CA2126619A CA2126619A1 CA 2126619 A1 CA2126619 A1 CA 2126619A1 CA 002126619 A CA002126619 A CA 002126619A CA 2126619 A CA2126619 A CA 2126619A CA 2126619 A1 CA2126619 A1 CA 2126619A1
Authority
CA
Canada
Prior art keywords
group
peptide
sustained
asp
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002126619A
Other languages
English (en)
French (fr)
Inventor
Yasutaka Igari
Hitoshi Ikeda
Masao Tsuda
Kazumichi Yamamoto
Mitsuhiro Wakimasu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of CA2126619A1 publication Critical patent/CA2126619A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57536—Endothelin, vasoactive intestinal contractor [VIC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA002126619A 1993-06-24 1994-06-23 Sustained-release preparation of anti-endothelin substance Abandoned CA2126619A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP153393/1993 1993-06-24
JP15339393 1993-06-24

Publications (1)

Publication Number Publication Date
CA2126619A1 true CA2126619A1 (en) 1994-12-25

Family

ID=15561515

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002126619A Abandoned CA2126619A1 (en) 1993-06-24 1994-06-23 Sustained-release preparation of anti-endothelin substance

Country Status (6)

Country Link
EP (1) EP0647449A1 (enExample)
KR (1) KR950000167A (enExample)
CN (1) CN1109780A (enExample)
CA (1) CA2126619A1 (enExample)
FI (1) FI943071A7 (enExample)
NO (1) NO942396L (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996007399A1 (en) * 1994-09-09 1996-03-14 Takeda Chemical Industries, Ltd. Sustained release preparation containing metal salt of a peptide
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5573762A (en) * 1995-04-24 1996-11-12 Genentech, Inc. Use of leukemia inhibitory factor specific antibodies and endothelin antagonists for treatment of cardiac hypertrophy
EP0815870A3 (en) * 1996-06-27 2000-05-03 Takeda Chemical Industries, Ltd. Composition for prohylaxis or treatment of cerebral infarction
AU4196697A (en) * 1996-09-16 1998-04-14 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
WO2000025803A1 (en) * 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Betacellulin protein-containing preparations
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
EP1277787A4 (en) * 2000-04-28 2009-11-11 Mitsubishi Tanabe Pharma Corp METHOD FOR PRODUCING MICROSPHERES
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
JP2004331750A (ja) 2003-05-02 2004-11-25 Canon Inc ポリヒドロキシアルカノエートを含有する磁性構造体及びその製造方法ならびにその用途
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
BRPI0620819A2 (pt) 2005-12-30 2011-11-22 Zensun Shangai Science & Technology Ltd uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
CA2911848A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for treating heart failure

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69220861T2 (de) * 1991-08-13 1997-11-20 Takeda Chemical Industries Ltd Zyklische Peptide und ihre Verwendung
TW333456B (en) * 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.

Also Published As

Publication number Publication date
KR950000167A (ko) 1995-01-03
FI943071L (fi) 1994-12-25
NO942396L (no) 1994-12-27
FI943071A7 (fi) 1994-12-25
EP0647449A1 (en) 1995-04-12
CN1109780A (zh) 1995-10-11
NO942396D0 (enExample) 1994-06-23
FI943071A0 (fi) 1994-06-23

Similar Documents

Publication Publication Date Title
US6376461B1 (en) Sustained-release preparation
CA2126619A1 (en) Sustained-release preparation of anti-endothelin substance
US6147051A (en) Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
AU2001283938A1 (en) Ghrelin antagonists
JP4180120B2 (ja) Ｌｈｒｈ−アンタゴニストの固定化及び活性安定化複合体及びその製法
CN101983068B (zh) N末端和c末端取代的人gh-rh拮抗类似物
JP2001501585A (ja) 拮抗活性を有するｈＧＨ―ＲＨ（１―２９）ＮＨ▲下２▼類似体
US20070042950A1 (en) Antagonistic analogs of gh rh (2003)
JP2002530432A (ja) Ｇｈ−ｒｈ阻害ｉｇｆ−ｉおよびｉｉの拮抗類似体
RU2248982C9 (ru) Антагонисты lhrh, их получение, фармацевтическая композиция и ее получение, способ лечения опухолей и бесплодия у млекопитающих
EP0655463A1 (en) Cyclic hexapeptides having endothelin antagonistic activity
JPH0592996A (ja) 心房性ナトリウム利尿因子活性をもつペプチド
EP0588873B1 (en) Treatment of liver cancer
US5753619A (en) Composition for prophylaxis or treatment of pulmonary circulatory diseases
HK1006947B (en) Treatment of liver cancer
KR20070083815A (ko) 고체상 합성에서 ｓ-알킬-술페닐 보호기
JPH0769917A (ja) 抗エンドセリン物質の徐放性製剤
JPH08157389A (ja) 高トリグリセリド血症治療剤
JPH08225456A (ja) 肺循環疾患予防治療剤
EP1198478A1 (en) Somatostatin analogs and their use for the treatment of cancer
JPH0789868A (ja) 臓器の手術または移植時に起こる臓器の機能低下の予防および／または治療剤
JPH08239325A (ja) 臓器の手術または移植時に起こる臓器の機能低下の予防および／または治療剤
JP3743794B2 (ja) ボンベシン類似体
CA3222510A1 (en) Ghr-binding pending peptide and composition comprising same
JPH10251160A (ja) 臓器の手術または移植時に起こる臓器の機能低下の予防および／または治療剤

Legal Events

Date Code Title Description
FZDE Discontinued